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Silveira WA, Gonçalves DA, Graça FA, Andrade-Lopes AL,
Bergantin LB, Zanon NM, Godinho RO, Kettelhut IC, Navegan-
tes LC. Activating cAMP/PKA signaling in skeletal muscle sup-
presses the ubiquitin-proteasome-dependent proteolysis: implications
for sympathetic regulation. J Appl Physiol 117: 11–19, 2014. First
published May 15, 2014; doi:10.1152/japplphysiol.01055.2013.—Al-
though we have recently demonstrated that plasma catecholamines
induce antiproteolytic effects on skeletal muscle (Graça FA, Gon-
çalves DAP, Silveira WA, Lira EC, Chaves VE, Zanon NM, Garófalo
MAR, Kettelhut IC, Navegantes LCC. Am J Physiol Endocrinol
Metab. 305: E1483-E1494, 2013), the role of the muscle sympathetic
innervation and, more specifically, norepinephrine (NE) in regulating
the ubiquitin (Ub)-proteasome system (UPS) remains unknown.
Based on previous findings that chemical sympathectomy acutely
reduces UPS activity, we hypothesized that muscle NE depletion
induces adrenergic supersensitivity in rat skeletal muscles. We report
that surgical sympathetic denervation (SDEN), a condition in which
only muscle NE from both hindlimbs is depleted, transiently reduced
the overall proteolysis and the UPS activity (25%) in both soleus
and extensor digitorum longus muscles. This antiproteolytic response
was accompanied by increased activity of adenylyl cyclase (112%),
levels of cyclic adenosine monophosphate (cAMP; 191%), and the
serine phosphorylation of cAMP response element-binding protein
(32%). In extensor digitorum longus from normal rats, NE (104 M)
in vitro increased the levels of cAMP (115%) and the serine phos-
phorylation of both cAMP response element-binding protein (2.7-
fold) and forkhead box class O1 transcription factor. Similar effects
were observed in C2C12 cells incubated with forskolin (10 M). In
parallel, NE significantly reduced the basal UPS (21%) activity and
the mRNA levels of atrophy-related Ub-ligases. Similar responses
were observed in isolated muscles exposed to 6-BNZ-cAMP (500
M), a specific PKA activator. The phosphorylation levels of Akt
were not altered by SDEN, NE, forskolin or 6-BNZ-cAMP. Our
results demonstrate that SDEN induces muscle adrenergic supersen-
sitivity for cAMP leading to the suppression of UPS, and that the
suppressive effects of NE on UPS activity and expression of Ub-
ligases can be mediated by the activation of cAMP/PKA signaling,
with the inhibition of forkhead box class O1 transcription factor.
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NOREPINEPHRINE (NE) IS A NEUROTRANSMITTER produced by sym-
pathetic nervous system (SNS), and it is released from sym-
pathetic fibers that are distributed widely to the whole body.
Although it is well known that skeletal muscles receive a
cholinergic motor innervation, evidence indicates that norad-
renergic nerve terminals make close contact with striated
muscle fibers in mammals (5, 6). However, the physiological
role of this autonomic innervation in regulating protein metab-
olism remains unclear.
Most of the metabolic actions of catecholamines in peripheral
tissues are exerted through a -adrenoceptor-mediated increase in
intracellular cyclic adenosine monophosphate (cAMP) and sub-
sequent activation of cAMP-dependent protein kinase (PKA)
and cAMP response element-binding protein (CREB). The
intracellular concentration of cAMP in cells is determined via
the balance between cAMP production by adenylyl cyclase
(AC), and cAMP degradation by phosphodiesterases (PDEs).
Catecholamines have been traditionally viewed as catabolic,
based on their lipolytic and glycogenolytic functions (27).
However, numerous pharmacological studies, reviewed in Refs.
25 and 33, have shown that 2-adrenergic agonists induce
hypertrophy of skeletal muscle and blunt muscle atrophy in
different conditions, including motor denervation, tumors, sep-
sis, and sarcopenia (13, 26, 40). The precise mechanism
through which 2-adrenergic agonists produce these effects is
not completely known, but they seem to be due, at least in part,
to a reduction in the rate of muscle protein breakdown (8, 16,
39). In fact, the in vitro addition of epinephrine (EPI) or NE
induces a reduction in the rate of overall proteolysis (37),
similar to that observed in human beings in vivo (17, 42). More
recently, our laboratory (21) and others (47) have demonstrated
that the short-term (3 days) or long-term (10 or 14 days)
clenbuterol treatment, a selective 2-adrenergic agonist, might
attenuate muscle atrophy through inhibitory effects on the
ubiquitin (Ub)-proteasome system (UPS), the main intracellu-
lar pathway for protein degradation in skeletal muscle (21, 26,
47). The Ub-conjugation to a protein substrate initiates its
degradation by the 26S proteasome complex. In a variety of
atrophy conditions, the processes of ubiquitination and degra-
dation are regulated by two muscle-specific Ub-protein ligases
(E3): atrogin-1/muscle atrophy F-box and MuRF1 (muscle
RING finger 1) (10, 19). These genes, coined “atrogenes,” are
regulated by Akt, a critical insulin signaling molecule that
regulates muscle mass. One mechanism by which Akt reduces
the expression of atrogenes involves the phosphorylation and
subsequent nuclear exclusion of the forkhead box transcription
factor Foxo (41, 44). Recent evidence indicates that atrogenes
may also be regulated by molecules that act through the cAMP
signaling pathway (9, 22). Indeed, the acute and chronic
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administration of clenbuterol to rodents suppressed the gene
expression of atrogin-1 and MuRF-1 in fast-twitch muscles
upon motor denervation (26) and fasting (20). These effects are
probably mediated by cAMP, as drugs that induce an increase
in the intracellular concentrations of cAMP, such as the selec-
tive and nonselective cAMP-PDE inhibitors, have also been
employed in preventing muscle atrophy in rodents (22). In-
deed, nonselective PDE inhibitors or rolipram, a selective
PDE-4 inhibitor, reduce the UPS activity and the atrogin-1
mRNA in isolated skeletal muscles from normal rats (30) and
in cultured muscle cells incubated with dexamethasone (20).
Although this evidence indicates that the cAMP signaling in
skeletal muscles is the mechanism by which catecholamines
suppress the Ub-ligases and the UPS, the physiological role of
muscle sympathetic innervation, and more specifically, NE, in
the control of this proteolytic process, has not been hitherto
investigated.
Previous work from our laboratory has shown that the
chemical sympathectomy with guanethidine for 2 days in-
creased the Ca2-dependent proteolysis in soleus, suggesting
that the SNS through catecholamines exerts an inhibitory
adrenergic tonus that restrains Ca2-dependent protein degra-
dation in oxidative muscles of normal rats (36). On the other
hand, it was also observed that the UPS activity in the extensor
digitorum longus (EDL) muscle was reduced after 2 days of
guanethidine treatment (36). This was interpreted as an anti-
proteolytic response to the adrenergic supersensitivity of the
EDL muscles following guanethidine treatment. Because in
that study both plasma and muscle catecholamine levels were
reduced by chemical sympathectomy, we could not dissociate
if the observed effects were due to plasma catecholamines or
NE released directly by noradrenergic innervation (36). To
investigate the specific role of NE in the control of skeletal
muscle protein synthesis in rodents, we have been using a
model of surgical sympathetic denervation (SDEN), a condi-
tion in which only muscle NE from both hindlimbs is depleted
(35). However, the consequences of SDEN on muscle protein
breakdown have not been examined. In the present studies, we
tested the hypothesis that SDEN induces skeletal muscle ad-
renergic supersensitivity and propose that NE may directly
suppress the UPS through a cAMP/PKA-dependent pathway.
Specifically, we have examined the in vivo effect of SDEN and
in vitro effect of NE and 6-BNZ-cAMP, a specific PKA
activator, on overall proteolysis, UPS activity and expression
of genes and proteins involved in muscle atrophy, and Akt/
Foxo signaling in isolated rat skeletal muscles. The muscle
cAMP levels, AC activity, the phosphorylation of CREB, as
well as Akt and Foxo 1, are also reported.
METHODS
Animals. Because the incubation procedure requires intact muscle
sufficiently thin to allow an adequate diffusion of metabolites and
oxygen (4), juvenile rats were used in all experiments. Male Wistar
rats (80–100 g) were housed in a room with a 12:12-h light-dark cycle
and were given free access to water and normal lab chow diet.
Animals were submitted to lumbar sympathetic denervation (SDEN)
to deplete the muscle NE content and killed by cervical dislocation 2,
3, 4, and 7 days after surgery. The duration of denervation/sympa-
thectomy was chosen because preliminary experiments showed that
36 h of sympathectomy were sufficient to significantly reduce the
skeletal muscles of NE (data not shown). For overall proteolysis
assay, we have used six or seven rats from each group and isolated
soleus or EDL muscles from one leg. After 2 h of incubation in the
presence or not of different compounds, muscles were removed and
stored at 80°C for RT-PCR experiments. Contralateral muscles
were removed and stored at 80°C for AC activity and [35S]guanos-
ine 5=-O-(3-thiotriphosphate) (GTPS)-binding assays. An additional
group composed of seven animals per group was used for muscle NE
and cAMP measurements. For the determination of proteolytic sys-
tems activities, we have used both muscles (left and right) from the
same animal. All rats were killed by cervical dislocation. The protocol
studies were approved by Ethical Commission of Ethics in Animal
Research from School of Medicine of Ribeirão Preto (017/2009) and
agree with Ethical Principles in Animal Research adopted by Brazil-
ian College of Animal Experimentation.
SDEN. The sympathetic denervation surgery was performed with
the help of a dissection microscope. For this, the animals were
anesthetized with ketamine and xylazine (85 and 10 mg/kg body wt ip,
respectively) and kept warm at 37°C on the heating bed during the
surgery and allowed to recover from anesthesia (30 min) before
being returned to their normal environment.
The SDEN consisted of the surgical excision of the bilateral second
and third lumbar ganglia of the paravertebral sympathetic chain, from
which arises the sympathetic fibers to the skeletal muscles of the rat
hindlimb (6). The lumbar sympathetic chain on both sides lies em-
bedded in connective tissue in front of the vertebral column, behind
the aorta and vena cava. Sham-operated animals were used as controls
(CON). Food consumption was not altered after 2, 3, 4, and 7 days of
surgery.
NE measurements. For the determination of muscle NE content, a
group of rats was killed 2, 3, 4, and 7 days after SDEN or sham
operation, and the EDL and soleus muscles from both hindlimbs (left
and right) were harvested and immediately frozen in liquid nitrogen
and then stored at80°C until assayed. NE was assayed as previously
described (18) using HPLC (LC-7A, Shimadzu Instruments) with a
Spherisorb ODS-2 (5 m; Sigma-Aldrich) reversed-phase column.
Incubation procedure. The EDL and soleus were rapidly dissected,
with care being taken to avoid damaging the muscles. Soleus were
maintained at approximately resting length by pinching their tendons
in aluminum wire supports, and EDL were maintained by pinning
them on inert plastic supports. Tissues were incubated at 37°C in
Krebs-Ringer bicarbonate buffer, pH 7.4, equilibrated with 95%
O2/5% CO2, containing glucose (5 mM).
Rates of protein degradation. For measurement of the rate of
overall proteolysis and proteolytic activities, skeletal muscles (EDL
and soleus) from CON and SDEN rats for 2, 3, 4, and 7 days were
incubated as described above. Briefly, after a 2-h incubation period,
the overall proteolysis and lysosomal and UPS activities were deter-
mined by measuring the rate of tyrosine release in the incubation
medium in the presence of cycloheximide (0.5 mM). Since muscle
cannot synthesize or degrade tyrosine, its release reflects the rate of
protein breakdown. Preliminary experiments showed that, as previ-
ously reported for normal animals (4), the intracellular pools of
tyrosine of the denervated rats were not significantly affected by all of
the incubation conditions used here. Therefore, rates of amino acid
release into the medium reflect rates of protein degradation.
For measurement of UPS activity, muscles from one limb were
incubated under conditions that prevent activation of the lysosomal
(10 mM methylamine and 1 U/ml insulin), branched-chain amino-
acid-dependent (170 M leucine, 100 M isoleucine, and 200 M
valine), and Ca2-dependent (Ca2-free medium with cysteine-pro-
tease inhibitors, including 25 M E64 and 50 M leupeptin) proteo-
lytic systems. Muscles from the contralateral limb were incubated in
the presence of both lysosomal and Ca2-dependent proteolytic sys-
tems inhibitors, plus the proteasome inhibitor MG132 (20 M).
For measurement of lysosomal activity, muscles from one limb
were incubated in the absence of methylamine, insulin, and branched-
chain amino acids, a condition in which the lysosomal system is
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activated. Contralateral muscles were incubated in the presence of
insulin (1 U/ml), leucine (170 M), isoleucine (100 M), valine (200
M), and methylamine (10 mM), a weak base that increases intralyso-
somal pH and inhibits lysosomal proteolysis. UPS and lysosomal
activities were calculated from the difference in tyrosine release
between the left and right muscles. Tyrosine release was assayed
using the fluorometric method (46).
Determination of muscle cAMP levels. The intracellular levels of
cAMP were measured in EDL and soleus muscles from CON and 3-
and 7-day SDEN rats by using a method based on a competitive
enzyme immunoassay system (GE Healthcare). Briefly, muscles were
homogenized in 6% trichloroacetic acid, and, after extraction of lipid
content with diethyl ether, the aqueous phase was lyophilized and
resuspended in the assay buffer.
AC activity assay. The AC activity was determined by measuring
the formation of cAMP in membrane fractions in EDL and soleus
muscles from CON and 3- and 7-day SDEN rats. Muscles were
homogenized in 10 volumes (weight/volume) 12.5 mM Tris, pH 7.4
(containing 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, and
1 mM pepstatin A), and the samples were centrifuged at 20,000 g for
10 min at 4°C. The pellet was suspended in the same buffer and
centrifuged two times at 20,000 g for 10 min at 4°C. The final pellet
was suspended in five volumes of the same buffer, and the protein
concentration was determined according to the method described by
Bradford (11) using bovine serum albumin (BSA) as standard. For the
AC activity assay, the membrane pellet containing 10 g of protein
were incubated at 30°C with 12.5 mM Tris, pH 7.4 (containing 0.6
mM ATP, 1 M GTP, 10 mM MgCl2, 1 mM IBMX, and 1 mg/ml
BSA) in the presence of 10 M forskolin (FSK) for 30 min. The
reaction was stopped by boiling the samples for 10 min, and the
samples were centrifuged for 15 min at 20,000 g. Cyclic AMP from
the supernatant was determined using the cAMP kit [3H]-assay system
(GE Healthcare, LifeSciences, Fairfield, CT) and expressed as pico-
moles of cAMP formed per hour per milligram of protein.
[35S]GTPS-binding assay for G protein activation. The basal and
activated G protein levels in EDL muscles from CON and 3-day
SDEN rats were determined using the procedure described previously
(2). Briefly, muscles were homogenized in 100 mg/ml (weight/
volume) 50 mM Tris·HCl buffer (pH 7.4) containing 3 mM MgCl2,
100 mM NaCl (reaction buffer), and 1 mM EGTA plus 0.32 M
sucrose. The samples were centrifuged two times at 1,000 g for 15
min at 4°C; the supernatant was mixed and centrifuged at 20,000 g for
30 min at 4°C. The final pellet was resuspended in five volumes of the
same buffer, and the protein concentration was determined according
to the method described by Bradford (11).
For the functional binding of [35S]GTPS, membranes were incu-
bated with reaction buffer plus 0.2 mM EGTA at 37°C in 200 l final
volume. To analyze the effect of G protein-coupled receptor-mediated
G protein activation on [35S]GTPS binding, membranes were incu-
bated with isoproterenol (0–100 M) in the presence of 30 M GDP,
at 37°C, in 200-l final volume. Nonspecific binding was obtained in
the presence of 50 M GTPS. Samples were centrifuged for 20 min
at 15,000 g at 4°C. To remove the free radioligand, the pellets were
rinsed with 1.0 ml reaction buffer and centrifuged for 20 min at
15,000 g at 4°C twice. The final pellet was suspended in 200 l of 1%
SDS, and the radioactivity was determined by scintillation counting
(Micro Beta Jet 1450, Perkin Elmer).
Quantitative PCR. Skeletal muscles were harvested and immedi-
ately frozen in liquid nitrogen. RNA was subsequently isolated from
individual skeletal muscles using TRIzol (Invitrogen, Carlsbad, CA).
Reverse transcription into cDNA was performed using 2 g of total
cellular RNA, 20 pmol oligo(dT) primer (Invitrogen), and Advantage
ImProm-II reverse transcriptase (Promega, Madison, WI). Real-time
PCR was carried out using an ABI7000 sequence detection system
(Applied Biosystems, Foster City, CA), a SuperScript III Platinum
SYBR Green One-Step RT-qPCR Kit with ROX (Invitrogen), and
primers for rat atrogin-1 (forward 5=-GCA GAG AGT CGG CAA
GTC-3= and reverse 5=-CAG GTC GGT GAT CGT GAG-3=), MuRF1
(forward 5=-TCG ACA TCT ACA AGC AGG AA-3= and reverse
5=-CTG TCC TTG GAA GAT GCT TT-3=), and cyclophilin B
(forward 5=-GCA TAC AGG TCC TGG CAT CT-3= and reverse
5=-CTT CCC AAA GAC CAC ATG CT-3=). The relative quantitation
of mRNA levels was plotted as the fold increase compared with the
respective CON group values. Transcripts of interest were normalized
to cyclophilin B levels. The level of the target transcripts was
calculated using the standard curve method (14).
Western blotting analysis. CREB, Akt, and Foxo1 phosphorylation
levels were measured in EDL muscles from CON and 3- and 7-day
SDEN rats. Skeletal muscles were homogenized in 50 mM Tris·HCl
buffer (pH 7.4) containing 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 1% sodium deoxycholate, 1% SDS, 10 mM sodium pyrophos-
phate, 100 mM sodium fluoride, 10 mM sodium orthovanadate, 5
g/ml of aprotinin, 1 mg/ml of leupeptin, and 1 mM phenylmethyl-
sulfonyl fluoride at 4°C. The homogenate was centrifuged at 21,000 g
at 4°C for 20 min, retaining the supernatant, and protein content was
determined using BSA as a standard (32). An equal volume of sample
buffer (20% glycerol, 125 mM Tris·HCl, 4% SDS, 100 mM dithio-
threitol, 0.02% bromophenol blue, pH 6.8) was added to the super-
natant, and the mixture was boiled. Thirty to one hundred micrograms
of total proteins were separated by SDS-PAGE, transferred to nitro-
cellulose membranes, and blotted with anti-Akt (1:750), anti-phospho
(p)-Ser473-Akt (1:750), anti-Foxo1 (1:1,000), anti-p-Ser256-Foxo1 (1:
750), anti-p-Ser133-CREB (1:750), and anti--actin (1:2,000). Pri-
mary antibodies (Ab) were detected using peroxidase-conjugated
secondary Ab (1:1,000 for Foxo1, p-Ser256 Foxo1, Akt, p-Ser473 Akt,
p-Ser133 CREB, and 1:5,000 for the other primary Abs) and visualized
using ECL reagents by an ImageQuant 350 detection system (GE
Healthcare, Piscataway, NJ). Band intensities were quantified using
ImageJ (version 1.43u, National Institutes of Health).
NE and 6-BNZ-cAMP in isolated skeletal muscles. To investigate
the in vitro effect of NE (104 M) and 6-BNZ-cAMP (500 M), the
cAMP analog that activates PKA, on the UPS activity, cAMP levels,
Ub-ligases mRNA expression (atrogin-1 and MuRF1), and protein
levels (CREB, Akt, and Foxo1), EDL muscles from normal rats were
incubated at different times in the presence, or absence, of each
compound using the same procedure described above. Contralateral
muscles were incubated with vehicle and used as CON.
Abs, drugs, and reagents. Rabbit polyclonal anti-p-Ser473-Akt,
anti-Akt, anti-p-Ser256-Foxo1, anti-Foxo1 and anti-p-Ser133-CREB
were purchased from Cell Signaling Technology (Danvers, MA).
Mouse anti--actin Ab was purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). All drugs and reagents were purchased from
Sigma-Aldrich (St. Louis, MO), Thermo Scientific HyClone (Pitts-
burgh, PA), Invitrogen (Carlsbad, CA), Calbiochem EMD Biosci-
ences (La Jolla, CA), or Amersham Biosciences (Piscataway, NJ).
Statistical analysis. The data are presented as means  SE. The
means from different groups were analyzed using paired or unpaired
Student’s t-tests. Multiple comparisons were made using one-way
ANOVA followed by a Student-Newman-Keuls post hoc test. P 
0.05 was taken as the criterion for significance.
RESULTS
Effect of sympathetic denervation on muscle NE. SDEN
from 2 to 7 days induced a significant reduction (85%) in NE
content of both EDL and soleus muscles (Fig. 1, A and B,
respectively). As previously shown (35), plasma levels of
catecholamines were not altered in this experimental model of
sympathectomy (Fig. 1, C and D). The surgery did not affect
body weight gain or skeletal muscle weight at any of the
experimental periods (data not shown). Averaged values for
EDL from CON and SDEN were, respectively (in mg/100 g):
at day 3 (40.8  1.3 and 42.4  0.8); at day 7 (45.0  1.0 and
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45.3  2.3); and at day 15 (46.8  1.1 and 46.8  0.8). For
soleus, averaged mass values from CON and SDEN were,
respectively (in mg/100 g body wt): at day 3 (49.7  0.7 and
49.8  1.0); at day 7 (45.5  2.2 and 46.6  2.1); and at day
15 (48.1  1.2 and 50.1  0.8).
Effect of sympathetic denervation on rates of protein
degradation. As shown in Fig. 2A, SDEN induced a 10–18%
decrease in overall proteolysis at 2, 3, and 4 days, but not at 7 days,
in both EDL and soleus muscles. In parallel, an25% decrease in the
UPS activity was observed in denervated EDL muscle after 2 and 3
days of surgery (Fig. 2B). However, after 4 and 7 days, UPS activity
in EDL reverted to control levels. In soleus muscle, the UPS
activity was significantly decreased by 20% at the three first
experimental intervals (2, 3, and 4 days), but not at 7th day
(Fig. 2B). Because the lysosomal pathway is one of the major
protein degradation systems in muscle cells, we investigated
the effect of SDEN on lysosomal proteolytic activity. In
contrast to UPS, the proteolytic activity of lysosomal pathway
in both soleus and EDL muscles was not altered by SDEN in
any time studied (Fig. 2C). These findings suggest that norad-
renergic innervation modulates the UPS activity in rat skeletal
muscles under control resting conditions.
Effect of sympathetic denervation on cAMP signaling. Be-
cause the majority of the intracellular effects of catecholamines in
skeletal muscle are mediated by cAMP, we investigated the
effects of SDEN on different components of the cAMP/PKA
signaling in EDL and soleus muscles of rats. As shown in Fig. 3A,
SDEN did not alter the EDL basal active pool of G proteins,
determined in the absence of isoproterenol. Also, the total
amount of G protein associated to EDL membranes was not
affected by denervation (data not shown). The addition of
isoproterenol to the incubation medium, at different concen-
trations, was able to activate G proteins by up to 137% in EDL
membranes of both CON and 3-day SDEN rats (Fig. 3A).
However, the cAMP levels was 191% higher in muscles of
SDEN compared with those of CON rats (Fig. 3C), which was
consistent with a 112% increase in AC activity induced by
SDEN (Fig. 3B). Furthermore, SDEN increased by 32% the
Ser phosphorylation levels of CREB, a well-known target of
PKA (Figs. 3, D and E). Figure 3D also shows that these
effects were not associated with phosphorylation of Akt and its
downstream target Foxo1, an effect that could prevent Foxo
translocation to the nucleus and UPS activation. The 3-day
SDEN-induced increase in AC activity and cAMP levels were
reverted to basal values 7 days after surgery (Fig. 3, B and C).
In soleus, 3-day SDEN also increased the AC activity (in pmol
cAMP/mg protein) in 334% (1,060.2  77.1 vs 244.0  14.7
in CON rats), an effect that was abolished 7 days after surgery
(366.9  47.3 vs 341.2  18.7 in CON rats). Taken together,
these data suggest that SDEN leads to a transitory adrenergic
supersensitivity for cAMP, secondary to the depletion of mus-
cle NE content.
In vitro effect of NE on UPS and cAMP/PKA and Akt/Foxo
signaling in isolated muscle. NE, at the concentration of 104
M, was added to the incubation medium of EDL muscle
isolated from normal rats. This concentration was used because
our laboratory has previously shown that it causes a statisti-
cally significant reduction in the overall proteolysis in EDL
muscle (37). As shown in Fig. 4A, NE reduced the UPS activity
by 21%. Additionally, NE reduced basal atrogin-1 (64%) and
MuRF1 (43%) mRNA levels (Fig. 4B). Similar effects were
observed in soleus muscle (data not shown). To verify whether
the observed effects of NE were mediated via activation of
cAMP/PKA signaling pathway, muscle cAMP levels and the
phosphorylation levels of CREB were assessed. NE increased
muscle cAMP levels by 115% (Fig. 4C) and the phosphoryla-
tion levels of CREB (2.7-fold) in EDL muscle (Fig. 4, D and
E), indicating increased PKA activity. As Akt/Foxo signaling
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can be regulated in EDL muscle by EPI in vitro (7), we
investigated the phosphorylation levels of Akt and Foxo1 in
isolated EDL muscles from normal rats in the presence of NE.
Interestingly, NE increased the Ser phosphorylation of Foxo1
(6-fold), but did not alter the Ser phosphorylation of Akt
(Fig. 4, D and E). Similar results were obtained in serum-
deprived C2C12 muscle cells incubated in the presence of FSK
(AC activator) (Fig. 5). Together, our results strength the
concept that NE exerts direct antiproteolytic actions in EDL
muscle of rats, and these effects are mediated, at least in part,
by increasing cAMP levels and inhibiting Foxo1 transcrip-
tional activity and the expression of Ub-ligases.
In vitro effect of 6-BNZ-cAMP on UPS and Akt/Foxo sig-
naling in isolated muscles. To investigate further the role of PKA
in the inhibitory effect of NE on UPS, EDL muscles were
incubated in the presence of 6-BNZ-cAMP (at the concentration
of 500 M), a specific PKA activator. As shown in Fig. 6, A and
B, 6-BNZ-cAMP significantly reduced the activity of UPS
(45%) and basal MuRF1 mRNA levels (40%), but did not alter
the atrogin-1 mRNA. Moreover, 6-BNZ-cAMP increased the
Ser phosphorylation levels of CREB (64%) after 30 min, and
the Ser phosphorylation levels of Foxo1 (3-fold) after 120
min of incubation (Fig. 6, C and D). Interestingly, the Ser
phosphorylation levels of Akt were not altered by 6-BNZ-
cAMP at any time interval (Fig. 6, C and D). Collectively,
these data suggest that the suppressive effect of PKA on UPS
activity and atrophy-related Ub-ligases expression is mediated
by the inhibition of Foxo1 and independently of Akt.
DISCUSSION
The present data show that the SDEN induced by surgical
excision at L2 and L3 levels of the sympathetic chain, which
innervates rat hindlimb skeletal muscles (6) transiently, de-
creased rates of total protein degradation in both fast- and
slow-twitch skeletal muscles. The lysosomal proteolytic sys-
tem did not participate in any of the changes observed, as the
activity of this system remained unchanged in soleus and EDL
throughout the experimental period (Fig. 2C). The present data
also show that the decrease in the rate of overall proteolysis (in
both soleus and EDL muscle, during the first 3 days) was
accompanied by a parallel decrease in the activity of UPS,
occurred without any change in plasma levels of cat-
echolamines (Fig. 1, C and D), and it was probably a direct
consequence of the depletion of muscle NE. This view is
consistent with a similar inhibition of the UPS, but not lyso-
somal activity, that was observed after a short-term adrenergic
blockade induced by guanethidine (36), a model of chemical
sympathectomy in which both plasma catecholamines and
muscle NE are reduced. This antiproteolytic response was
interpreted as an adaptive mechanism of the muscle to limit
protein breakdown. The present study reinforces this hypoth-
esis and shows, for the first time, that the inhibition of overall
protein breakdown and UPS was clearly associated with an
increase in the activity of AC and, as consequence, in the levels
of cAMP, which in turn induced CREB activation, possibly via
PKA (Figs. 2 and 3). It is interesting to note that the biphasic
pattern of proteolysis observed in muscles from denervated
rats, with an initial decrease during the first 3 days, followed by
a return to the CON values after 7 days (Fig. 2), has also been
observed for cAMP and the activity of AC in both EDL and
soleus muscles (Fig. 3, B and C). Taken together, these data
strongly suggest that SDEN induces skeletal muscle adrenergic
supersensitivity for cAMP, leading to the suppression of UPS
activity under normal conditions, when circulating catecholamines
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Ser473), and forkhead box class O1 transcrip-
tion factor (Foxo1) (p-Ser256) (D and E) in
rat EDL muscles. Phosphorylated proteins
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are at normal levels. These data confirm previous investigations
demonstrating that chemical and/or surgical sympathectomy
induce the development of adaptive supersensitivity in a num-
ber of tissues, including cerebral cortex and cardiac muscle
(43, 45). Indeed, the mechanisms underlying sympathectomy-
induced adrenergic supersensitivity may include multiple steps
of action. The depletion of NE in different tissues leads to an
increased number of -adrenergic receptors (45) and/or an
alteration in the intracellular transduction processes responsi-
ble for the action of an agonist following receptor occupation
by that agent (43). The present finding that the increases in AC
activation were not correlated with any detectable change in
the levels or activity of G protein (Fig. 3A) suggests that the
cellular mechanism that underlies the development of adaptive
supersensitivity in the rat skeletal muscle may involve a mod-
ification of AC. The subsequent decrease to basal levels in the
AC activity observed after 7 days of denervation can be
interpreted as a restoration of muscle capacity to limit the
cAMP increase (1) and can be advantageous for maintaining
the rate of muscle protein degradation. The mechanism of the
temporary nature of the increased adrenergic sensitivity in
denervated skeletal muscles cannot be explained on the basis of
the present data.
Although our in vivo data suggest that the adrenergic super-
sensitivity induced by SDEN inhibited the UPS activity, it
could be argued that this response was a consequence of the
lack of NE itself, which would imply that this neurotransmitter
acts as a potential activator of UPS system. Alternatively,
decreased muscle NE content by lumbar surgical excision
could act indirectly by changing insulin responsiveness (24), or
regional blood flow. In fact, a significant increase in muscle
blood flow following chronic lumbar sympathectomy has been
reported in dogs (28). However, these possibilities seem un-
likely, since previous studies from our laboratory have con-
vincingly shown that both catecholamines, EPI and NE, exert
a direct inhibitory control of proteolysis in rat skeletal muscle,
with the participation of a cAMP-dependent pathway (37, 38).
In agreement, the present data show that NE in vitro increased
muscle cAMP levels (Fig. 4C) and in parallel inhibited the
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activity of UPS (Fig. 4A) and the gene expression of the
atrogin-1 and MuRF1 (Fig. 4B). These adrenergic effects are
probably mediated by 2-adrenoceptors, given that clenbuterol,
and drugs that induce an increase in the muscle cAMP levels,
such as the selective and nonselective cAMP-PDE inhibitors,
decreased the basal activity of UPS, levels of Ub-protein
conjugates, and expression of atrogin-1 mRNA (20, 21, 30).
Accordingly, previous studies have shown that sympathetic
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hyperactivity in 3-mo-old mice lacking both 	2A- and 	2C-
adrenergic receptor subtypes (	2A-/	2CARKO mice) induces
hypertrophy in white skeletal muscle, an effect that is associ-
ated with suppression of UPS activity (3, 15). Taken together,
these findings suggest that NE released from nerve terminals,
through the cAMP signaling, plays a role in suppressing the
Ub-proteasome-dependent protein breakdown under normal
conditions and implies that the SNS has an antiproteolytic
effect in skeletal muscle of rats. Furthermore, catecholamines
may act directly on skeletal muscle, not only to decrease
proteolysis, but also to increase rates of muscle protein syn-
thesis, especially in situations where the basal rates of protein
synthesis are already reduced (35). Therefore, the reduction of
proteolysis and/or stimulation of protein synthesis are adren-
ergic mechanisms that could explain part of the attenuation of
atrophy observed through the application of blood flow restric-
tion, a maneuver that increase plasma levels of NE in human
beings without exercise (31).
Furthermore, we investigated whether or not the in vitro
effects of NE on UPS could involve the activation of the
canonical cAMP/PKA signaling pathway. It is well-established
that the expression of Ub-ligases and the consequent activation
of the proteasome are inhibited by the activation of phospha-
tidylinositol 3-kinase/Akt signaling pathway through the phos-
phorylation and nuclear exclusion of Foxo transcription factors
(41, 44). Because the production of cAMP on EPI stimulation
in isolated muscles may activate Akt/Foxo signaling and in-
hibit proteolysis (7, 12), we first postulated that NE would
affect this signaling pathway. Interestingly, the data show that
NE in vitro increased the Ser phosphorylation levels of CREB
and Foxo1, but did not alter the Ser phosphorylation of Akt
(Fig. 4, D and E). Similar effects were obtained in serum-
deprived C2C12 muscle cells incubated with FSK (a specific
AC activator), suggesting that cAMP and probably PKA me-
diate the inhibitory actions of NE on Ub-ligases in vitro (Fig.
5). To further support the notion that NE exerts inhibitory
effects on UPS through a PKA-dependent signaling, EDL
muscle from normal rats were incubated in the presence of
6-BNZ-cAMP, a specific PKA activator. The present data
clearly show that the direct activation of PKA in vitro induced
by 6-BNZ-cAMP decreased the UPS activity (Fig. 6A) and
MuRF1 mRNA (Fig. 6B) and in parallel increased the Ser
phosphorylation levels of CREB and Foxo1, without altering
Akt phosphorylation (Fig. 6, C and D). In contrast to the effect
of NE in isolated muscle, the 6-BNZ-cAMP did not alter the
expression of atrogin-1 mRNA (Fig. 6B). On the other hand,
6-BNZ-cAMP reduced the mRNA levels of atrogin-1 in C2C12
muscle cells under nutritional stress (data not shown). In
agreement with these findings, we have recently found that
6-BNZ-cAMP in vitro significantly suppressed the expression
of MuRF1 mRNA in normal and atrophying soleus muscles,
but had no effect on atrogin-1 mRNA (21). The available data
do not allow any conclusion about the reason for these differ-
ences between MuRF1 and atrogin-1, but the lack of respon-
siveness of the atrogin-1 mRNA to the 6-BNZ-cAMP could be
explained, at least in part, by the fact that the stimulatory effect
of the 6-BNZ-cAMP on the phosphorylation levels of Foxo1
and CREB was less potent compared with NE (Figs. 4 and 6).
To our knowledge, this constitutes the first report that Foxo1
may be a direct substrate for PKA in skeletal muscle cells, a
finding that strongly supports similar conclusions in vascular
endothelial cells (29). Further experiments are needed to cer-
tify if PKA may directly phosphorylate and inhibit transcrip-
tional activity of Foxo1 under physiological conditions in
intact skeletal muscles.
In summary, the present data show that the surgical SDEN
induces the phenomenon of adrenergic supersensitivity for
cAMP that is associated with suppression of the basal activity
of UPS in EDL and soleus muscles. Furthermore, as shown in
Fig. 7, the inhibitory effect of NE on UPS observed in vitro
may be mediated through cAMP/PKA activation, leading to
the inhibition of Foxo1 transcription factor by phosphorylation
and a consequent suppression of atrophy-related Ub-ligases.
Based on these data and assuming that the NE released by the
sympathetic innervation acts on skeletal muscle through the
same mechanisms, the antiproteolytic effects of sympathetic
denervation here observed might be an important adaptative
effect for preservation of proteins. Finally, these results repre-
sent further evidence on the antiproteolytic role of SNS in
skeletal muscle and suggest that modulating the cAMP/PKA
signaling may serve as a potential target for muscle-wasting
conditions in populations characterized by sympathetic dys-
function, such as spinal cord-injured adults.
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